Literature DB >> 19433568

Data mining validation of fluconazole breakpoints established by the European Committee on Antimicrobial Susceptibility Testing.

Isabel Cuesta1, Concha Bielza, Pedro Larrañaga, Manuel Cuenca-Estrella, Fernando Laguna, Dolors Rodriguez-Pardo, Benito Almirante, Albert Pahissa, Juan L Rodríguez-Tudela.   

Abstract

European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints classify Candida strains with a fluconazole MIC < or = 2 mg/liter as susceptible, those with a fluconazole MIC of 4 mg/liter as representing intermediate susceptibility, and those with a fluconazole MIC > 4 mg/liter as resistant. Machine learning models are supported by complex statistical analyses assessing whether the results have statistical relevance. The aim of this work was to use supervised classification algorithms to analyze the clinical data used to produce EUCAST fluconazole breakpoints. Five supervised classifiers (J48, Correlation and Regression Trees [CART], OneR, Naïve Bayes, and Simple Logistic) were used to analyze two cohorts of patients with oropharyngeal candidosis and candidemia. The target variable was the outcome of the infections, and the predictor variables consisted of values for the MIC or the proportion between the dose administered and the MIC of the isolate (dose/MIC). Statistical power was assessed by determining values for sensitivity and specificity, the false-positive rate, the area under the receiver operating characteristic (ROC) curve, and the Matthews correlation coefficient (MCC). CART obtained the best statistical power for a MIC > 4 mg/liter for detecting failures (sensitivity, 87%; false-positive rate, 8%; area under the ROC curve, 0.89; MCC index, 0.80). For dose/MIC determinations, the target was >75, with a sensitivity of 91%, a false-positive rate of 10%, an area under the ROC curve of 0.90, and an MCC index of 0.80. Other classifiers gave similar breakpoints with lower statistical power. EUCAST fluconazole breakpoints have been validated by means of machine learning methods. These computer tools must be incorporated in the process for developing breakpoints to avoid researcher bias, thus enhancing the statistical power of the model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19433568      PMCID: PMC2704684          DOI: 10.1128/AAC.00081-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Has antifungal susceptibility testing come of age?

Authors:  John H Rex; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2002-09-24       Impact factor: 9.079

Review 2.  Machine learning in bioinformatics.

Authors:  Pedro Larrañaga; Borja Calvo; Roberto Santana; Concha Bielza; Josu Galdiano; Iñaki Inza; José A Lozano; Rubén Armañanzas; Guzmán Santafé; Aritz Pérez; Victor Robles
Journal:  Brief Bioinform       Date:  2006-03       Impact factor: 11.622

Review 3.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

4.  Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003.

Authors:  Benito Almirante; Dolors Rodríguez; Benjamin J Park; Manuel Cuenca-Estrella; Ana M Planes; Manuel Almela; Jose Mensa; Ferran Sanchez; Josefina Ayats; Montserrat Gimenez; Pere Saballs; Scott K Fridkin; Juliette Morgan; Juan L Rodriguez-Tudela; David W Warnock; Albert Pahissa
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

Review 5.  ARTs versus ASTs: where are we going?

Authors:  C C Sanders
Journal:  J Antimicrob Chemother       Date:  1991-11       Impact factor: 5.790

6.  Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans.

Authors:  F Laguna; J L Rodríguez-Tudela; J V Martínez-Súarez; R Polo; E Valencia; T M Díaz-Guerra; F Dronda; F Pulido
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

7.  Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia.

Authors:  Juan L Rodríguez-Tudela; Benito Almirante; Dolors Rodríguez-Pardo; Fernando Laguna; J Peter Donnelly; Johan W Mouton; Albert Pahissa; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

  7 in total
  3 in total

1.  Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST).

Authors:  Isabel Cuesta; Concha Bielza; Manuel Cuenca-Estrella; Pedro Larrañaga; Juan L Rodríguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2010-02-01       Impact factor: 5.191

2.  Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis.

Authors:  E P Garvey; W J Hoekstra; R J Schotzinger; J D Sobel; E A Lilly; P L Fidel
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

3.  Optimal Regimens and Clinical Breakpoint of Avilamycin Against Clostridium perfringens in Swine Based on PK-PD Study.

Authors:  Anxiong Huang; Xun Luo; Zihui Xu; Lingli Huang; Xu Wang; Shuyu Xie; Yuanhu Pan; Shiwei Fang; Zhenli Liu; Zonghui Yuan; Haihong Hao
Journal:  Front Pharmacol       Date:  2022-02-24       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.